2020/04/09 COVID-19: Analysis of the Emerging Disease Landscape – March 2020
A range of players – from pharma & biotech firms to academic institutions & government agencies – have thrown their hats in the ring.COVID-19: Analysis of the Emerging Disease Landscape
Single User License: $2,495
Report format: PPT
In rare instances, coronavirus variants have been known to cause severe disease in humans. There are three such cases: severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.
The COVID-19 therapeutic pipeline consists of 89 drugs spanning all stages of development (discovery to Phase III); 16 of these drugs have reached clinical-stage development, Phases I–III. The pipeline is largely in the early stage, with approximately 69% of the drugs in discovery and preclinical phases.
The lack of a vaccine means that the outbreak has spread nearly unabated, slowed only by such prevention measures as social distancing without the benefit of any vaccine-conferred immunity in the population.
For patients diagnosed with COVID-19, the unavailability of any treatments proven to be efficacious in relieving symptoms and treating the underlying disease means that supportive care is the only therapeutic option.
Report Scope:
- Global epidemiology metrics and trends - Snapshot of epidemiological trends to date in the top three most-affected countries
- An overview of the pipeline for antivirals and vaccines
- Summary of available efficacy data
- An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- Highlights in deal-making trends, particularly public-private partnerships
